April 23rd 2024
No differences in efficacy and safety were seen in a study cohort of 1325 patients undergoing frontline treatment with lenvatinib for unresectable hepatocellular carcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Pembrolizumab Plus Lenvatinib Misses Primary End Points in Unresectable HCC
August 5th 2022While treatment with pembrolizumab and lenvatinib vs lenvatinib alone seemed to have survival benefit in patients with unresectable hepatocellular carcinoma, the primary end points of the trial were missed.
Read More
Cabozantinib Plus Atezolizumab Improved Progression-Free Survival in Patients with HCC Vs Sorafenib
July 21st 2022In COSMIC-312, reduction in the risk of disease progression or death was achieved with the combination of cabozantinib Plus atezolizumab compatient with sorafenib in patient with hepatocellular carcinoma.
Read More
Finn Reviews Options and Dosing for a Patient With Unresectable HCC
June 21st 2022During a Targeted Oncology case-based roundtable event, Richard S. Finn, MD, discussed the case of a patient with hepatocellular cancer with a medical history of Crohn disease, cirrhosis, and variceal bleeding.
Read More
Viral Etiology, NLR Lead to Better Responses With Atezolizumab/Bevacizumab Combo in HCC
March 23rd 2022Treatment with atezolizumab plus bevacizumab in the first-line setting achieved better responses for patients with unrespectable hepatocellular carcinoma when their disease had a viral versus nonviral etiology and neutrophil-to-lymphocyte ratio was less than 3.6.
Read More
Cabozantinib Plus Atezolizumab Shows No Overall Survival Benefit in HCC
March 15th 2022Cabozantinib in combination with atezolizumab shows no effect on survival compared to sorafenib in patients with previously untreated advanced hepatocellular carcinoma based on results from the final analysis of the phase 3 COSMIC-312 trial.
Read More
Part 1: Selecting Systemic Therapy in HCC With Serious Comorbidities
March 11th 2022During a live virtual event, Pierre Gholam, MD, discussed treatment options for a patient with hepatocellular carcinoma who had serious medical conditions including cirrhosis, Crohn's disease, and variceal bleeding.
Read More